Amgen Ties Increased Transfusions To ESA Scrutiny in NCD Review Request
Executive Summary
Amgen has released an internally generated analysis of data that draws a causal link between an increase in blood transfusions and the heightened scrutiny erythropoiesis-stimulating agents have received this year
You may also be interested in...
Amgen Plans Seven ESA Risk Studies After Latest Safety Update To Labeling
Amgen is expanding its pharmacovigilance program for Aranesp and Epogen with seven new clinical trials to study risks associated with using erythropoiesis-stimulating agents to treat anemia in patients with cancer
Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach
CMS has abandoned the idea of limiting some uses of erythropoiesis-stimulating agents to a research trial setting, despite receiving public comments that the "coverage with evidence development" approach may be acceptable in some circumstances
EPO Scathed But Survives ODAC Challenge; Cmte. Calls For Additional Trials
Sponsors of erythropoiesis-stimulating agents should conduct additional safety studies to support continued marketing in the oncology setting, FDA's Oncologic Drugs Advisory Committee unanimously recommends